Beneski Benjamin Machinas 4
4 · Allogene Therapeutics, Inc. · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
Allogene (ALLO) SVP Beneski Sells 4,835 Shares
What Happened
Beneski Benjamin Machinas, SVP and Chief Technical Officer of Allogene Therapeutics, sold 4,835 shares on 2026-03-16 in open-market transactions for a total of approximately $11,942 (weighted average price reported as $2.47). The filing indicates this was a mandated "sell-to-cover" to satisfy tax withholding related to the vesting of restricted stock units, not a discretionary sale.
Key Details
- Transaction date: 2026-03-16; Form 4 filed: 2026-03-18 (timely filing).
- Shares sold: 4,835; reported weighted average price: $2.47; price range across transactions: $2.46–$2.47.
- Total proceeds reported: ~$11,942.
- Footnote F1: Sale was required by the issuer’s equity plan to cover tax withholding for RSU vesting — not a voluntary trade by the insider.
- Footnote F2: Price is a weighted average; the filer will provide breakdown of shares sold at each price upon request.
- Shares owned after the transaction: not provided in the supplied data.
Context
Sell-to-cover transactions are a common administrative step when RSUs vest and generally reflect tax withholding mechanics rather than a signal about an insider’s view of the company. The filing appears timely (filed two days after the transaction).
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-16$2.47/sh−4,835$11,942→ 198,205 total
Footnotes (2)
- [F1]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.46 to $2.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.